Helus Pharma Inc. will host a webcast Monday at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study of HLP003 in major depressive disorder, according to a company announcement reported by Investing.com.
The company describes HLP003 as a novel serotonergic agonist being developed as an adjunctive treatment for major depressive disorder. The U.S. Food and Drug Administration has granted the drug candidate Breakthrough Therapy Designation, the company said in a press release.
The webcast will be available on the Events & Presentations page of the company's website, with an archived version to follow. The source does not report the trial results themselves.
Helus Pharma is also developing HLP004, a second serotonergic agonist in Phase 2 development for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom and Ireland, and trades on the Nasdaq Global Market and Cboe Canada under the ticker HELP.